TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20522283
Drug: Circumferential casting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential casting (CC)
Study: 20522283
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (CC, VDS, MST)
Study: 11876600
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) with pullulan‐conjugated antigen (CS‐560)
Study: 10992846
Drug: Deep topical
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep topical fornix nerve block anaesthesia (DTFNBA)
Study: 9001651
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (ACV) 5‐80 mg/kg daily in four divided doses
Study: 1483856
Drug: Vigabatrin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (2 g/day)
Study: 1483856
Drug: Vigabatrin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (dose titration up to 4 g/day)
Study: 4006263
Drug: Topical phenylpropanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical phenylpropanolamine (PPA) 25 mg/ml
Study: 27576846
Drug: HDM2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HDM2 inhibitor SAR405838
Study: 25065489
Drug: Buprenorphine pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine pharmacotherapy and behavioral treatment
Study: 17957000
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CrM) supplementation (loading phase, 20 g/day x 3 days; maintenance phase, 5 g/day x 7 days)
Study: 7731108
Drug: recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant growth hormone (r‐hGH) at a dose of 0.5 IU/kg/week
Study: 7731108
Drug: recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant growth hormone (r‐hGH) at a dose of 1.0 IU/kg/week
Study: 3076118
Drug: Gemfibrozil 600mg
Normalized name: GEMFIBROZIL 600MG TAB
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 600mg twice daily
Study: 24916951
Drug: 3-month exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month exercise intervention (160 min/week of moderate intensity aerobic walking, twice weekly resistance training with resistance bands, and six discussion groups)
Study: 24370303
Drug: Tetrandrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrandrine (100 mg) twice a day + Acetylcysteine effervescent tablets (600 mg) twice a day
Study: 24370303
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (anti-inflammatory, antitussive, and antiasthmatic drugs)
Study: 21385365
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy plus standard wound care
Study: 16815864
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with celecoxib 200 mg once daily
Study: 16815864
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with celecoxib 200 mg once daily
Study: 2682474
Drug: Naloxone 4
Normalized name: naloxone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 4 mg i.v.
Study: 334219
Drug: Nomifensine 75
Normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomifensine 75 mg
Study: 11193231
Drug: Desipramine 50
Normalized name: desipramine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 50 mg
Study: 31160472
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (topical numbing cream, positioning, distraction by a specialized pain nurse)
Study: 27445468
Drug: UMEC 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 62.5 µg
Study: 27445468
Drug: VI 25
Normalized name: VITRAKVI 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VI 25 µg
Study: 22723325
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 μg once daily
Study: 22572567
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel used topically twice daily for 2 weeks
Study: 22572567
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole cream used topically twice daily for 2 weeks
Study: 19235039
Drug: Broccoli intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli intake (200 g)
Study: 15485530
Drug: CO(2) laser
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO(2) laser treatment
Study: 15485530
Drug: Glucantime treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime treatment
Study: 7988089
Drug: Aspirin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (30 to 283 mg)
Study: 2511610
Drug: Pirbuterol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 20 mg thrice daily for 6 months
Study: 31351491
Drug: Oral cotrimoxazole
Normalized name: clotrimazole Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cotrimoxazole
Study: 31351491
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (dry mopping and ciprofloxacin drops) plus dilute povidone-iodine ear wash
Study: 31351491
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (dry mopping and ciprofloxacin drops) plus placebo
Study: 24120480
Drug: Perioperative FOLFOX4
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative FOLFOX4 chemotherapy (6 cycles of oxaliplatin 85mg/m², folinic acid 200 mg/m² or 100 mg/m², fluorouracil 400 mg/m² bolus and 600 mg/m² continuous infusion)
Study: 24120480
Drug: Perioperative FOLFOX4
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative FOLFOX4 chemotherapy
Study: 21145193
Drug: Group MgSO(4)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MgSO(4) - 50mg of magnesium sulphate 5% (1.0 mL) added to 25 μg of fentanyl citrate (0.5 mL) and 300 μg of morphine
Study: 21145193
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group S - 25 μg of fentanyl citrate (0.5 mL) + 300 μg of morphine + 1.0 mL of preservative-free 0.9% sodium chloride
Study: 18287358
Drug: CLA-rich fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA-rich fat (115 g/d, 5.5 g/d CLA oil, 39.4% cis9, trans11 and 38.5% trans10, cis12)
Study: 12543892
Drug: Normal haemoglobin
Normalized name: Abnormal haemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal haemoglobin (135-160 g/l)
Study: 12543892
Drug: Subnormal haemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subnormal haemoglobin (90-120 g/l)
Study: 10987585
Drug: Eptifibatide (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (180 microg/kg bolus + continuous infusion of 2.0 microg/kg/min for ≤96 h)
Study: 8011251
Drug: Potentially antitoxoplasmic
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially antitoxoplasmic drugs (trimethoprim‐sulphamethoxazole, pyrimethamine, dapsone, pyrimethamine‐sulphadoxine, sulphadiazine)
Study: 2891797
Drug: VEPA or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEPA or VEPA-M therapy
Study: 26600459
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with ART for 12 months
Study: 12691976
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) curriculum workshop series (ten sessions) introduced in 2000
Study: 10871576
Drug: 0.7 g
Normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g protein/kg
Study: 10871576
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g protein/kg
Study: 10871576
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g protein/kg
Study: 10871576
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g protein/kg
Study: 8256784
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral cholera vaccine CVD 103‐HgR (5 x 10(8) colony forming units)
Study: 3572463
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation chemotherapy (four courses)
Study: 23752057
Drug: 18 mcg
Normalized name: Spiriva, 18 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mcg tiotropium
Study: 23752057
Drug: 18 mcg
Normalized name: Spiriva, 18 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mcg tiotropium plus 12 mcg formoterol
Study: 22735462
Drug: Sugammadex 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 32 mg/kg
Study: 20825252
Drug: Sugammadex 64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 64 mg/kg
Study: 20825252
Drug: Sugammadex 96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 96 mg/kg
Study: 16010547
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 2 ml of sterile saline into the pack prior to opening
Study: 16010547
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection of saline into the pack prior to opening
Study: 1678392
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (100, 200, 500, 1000 micrograms)
Study: 24346811
Drug: Extended-release paliperidone
Normalized name: paliperidone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release paliperidone (paliperidone ER) 6 mg
Study: 24346811
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone (mean dose: 4.0 mg)
Study: 24346811
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from oral risperidone to paliperidone ER
Study: 21121492
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (CBT) intervention program, conducted over four consecutive 1.5-hour weekly sessions.
Study: 12006131
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day
Study: 7751526
Drug: Antihistamine and
Normalized name: Antihistamine and Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine and anti-inflammatory medicines timed to the day-night temporal pattern in symptom manifestation and intensity.
Study: 7751526
Drug: Traditional equal-interval,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional equal-interval, equal-dose medication schedules.
Study: 401194
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg bolus of methylprednisolone
Study: 401194
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg bolus of methylprednisolone
Study: 24331203
Drug: Medication Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Adherence (MA)
Study: 11739353
Drug: Traditional bonesetters
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional bonesetters (TBS) treatment
Study: 11739353
Drug: Orthodox treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodox treatment in hospital
Study: 28591764
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement (W)
Study: 25399618
Drug: New combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: New combination of retinoids and depigmenting agents
Study: 20354468
Drug: Psychomotor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychomotor therapy (home program and 3 outpatient sessions)
Study: 20354468
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (home program focusing on pain contingent training of back, abdominal, and leg muscle functional strength and endurance, stretching, and cardiovascular fitness)
Study: 20354468
Drug: Psychomotor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychomotor therapy
Study: 18845961
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 1440 UI of hepatitis A vaccine (HAVRIX) at weeks 0, 4, and 24
Study: 18845961
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of hepatitis A vaccine 24 weeks apart
Study: 14642682
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg/day)
Study: 8977984
Drug: 1M depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1M depot formulation
Study: 8977984
Drug: 3M depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3M depot formulation
Study: 1608405
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Heparin and Aspirin)
Study: 1608405
Drug: Neither treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither treatment (placebo)
Study: 26361994
Drug: Venlafaxine (18.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (18.75 mg/day)
Study: 19809363
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg once daily for 4 weeks, then randomized to valsartan 160, 320, or 640 mg/day for 26 weeks
Study: 19809363
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 or 640 mg/day
Study: 16197283
Drug: Fast ForWord
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast ForWord (FFW) intervention, home-based therapy for 6 weeks
Study: 11834877
Drug: Dilazep dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep dihydrochloride (300 mg/day, n = 20)
Study: 7258754
Drug: Bretylium tosylate
Normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bretylium tosylate (10 mg/kg)
Study: 26786042
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg three times daily for 3 days)
Study: 21136333
Drug: 5-day glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day glucocorticoid treatment followed by 9 days of placebo
Study: 21136333
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of systemic glucocorticoids (40 mg of prednisone-equivalent daily)
Study: 14706762
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein containing 99 mg naturally occurring isoflavones
Study: 11871584
Drug: Assured Treatment
Normalized name: Assured Pain Relief KIT
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assured Treatment (AT)
Study: 11871584
Drug: Disbeliever Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disbeliever Treatment (DT)
Study: 11871584
Drug: Non-Targeted Treatment
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Targeted Treatment (NT)
Study: 9926278
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 2‐8 mg/day orally for 8‐12 weeks
Study: 7819982
Drug: DICE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DICE therapy
Study: 7819982
Drug: Red dice
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red dice therapy
Study: 28070889
Drug: Guided parent-delivered
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided parent-delivered cognitive behaviour therapy (CBT)
Study: 26047719
Drug: Parent presence
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent presence during speech preparation (N=39)
Study: 26047719
Drug: Stranger presence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stranger presence during speech preparation
Study: 26047719
Drug: Parent presence
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent presence during speech preparation
Study: 23115341
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change condition (yellow tablet 'Betaprol')
Study: 23115341
Drug: Generic change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic change condition (white tablet 'Generic')
Study: 23115341
Drug: Branded change
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded change condition (white tablet 'Novaprol')
Study: 540525
Drug: Piracetam (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2.4 g per day)
Study: 31125823
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg tid for 14 days
Study: 20073212
Drug: Compound salvia
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound salvia injection (20 mL in 10% glucose 500 mL for intravenous dripping once a day) and UDCA (15 mg, thrice daily by oral taken)
Study: 17526181
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (Control group II)
Study: 2591060
Drug: Octreotide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (250 micrograms/day in 4 divided s.c. injections for 1 month, followed by continuous s.c. infusions for another month, then 200 micrograms three times daily as s.c. injections)
Study: 22379151
Drug: Octreotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide treatment
Study: 31833226
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (1 day and 4 days)
Study: 31833226
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (4 days)
Study: 28291237
Drug: 4-L split-dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-L split-dose polyethylene-glycol (PEG) regimen
Study: 28291237
Drug: 2-L split-dose
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L split-dose PEG plus ascorbic acid (PEG+Asc) regimen
Study: 21866432
Drug: Hydrocortisone 1
Normalized name: hydrocortisone 1 MG
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 1 mg·kg(‐1) iv
Study: 21866432
Drug: Hydrocortisone 2
Normalized name: hydrocortisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 2 mg·kg(‐1) iv
Study: 11777191
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate liquid suspension 800 mg/day
Study: 11777191
Drug: Dronabinol tablets
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol tablets 2.5 mg b.i.d.
Study: 11777191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of megestrol acetate and dronabinol
Study: 8027215
Drug: Octreotide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (4 months treatment)
Study: 2917597
Drug: Viqualine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viqualine 75 mg bd
Study: 2917597
Drug: Ethanol (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (blood alcohol concentrations of 17-22 mmol.l-1)
Study: 4149613
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and other beta-blockers
Study: 28057361
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Study: 28057361
Drug: adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab (80 mg week 0, then 40 mg week 1, and every 2 weeks through week 23)
Study: 11403980
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DHEA daily for 13 weeks
Study: 9409946
Drug: Quinolones (ciprofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinolones (ciprofloxacin, 500 mg/12 h per os; pefloxacin, 200 mg/12 h intravenous)
Study: 9409946
Drug: Tetracyclines (rolitetracycline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracyclines (rolitetracycline, 275 mg/12 h intravenous)
Study: 8323891
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (1.0 mcg.kg‐1h‐1)
Study: 8323891
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (0.5 mcg.kg‐1 x h‐1) and clonidine (0.3 mcg.kg‐1 x h‐1)
Study: 3095503
Drug: Triple-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug combination of methotrexate (MTX), 5-fluorouracil (5-FU), and cisplatin
Study: 29298124
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 μg twice/day
Study: 29298124
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 μg twice/day